About Pricing FAQs Providers Trials Blog

Back to your record

Login Get started

Finding studies

Your health journey, clearly organized.

Questions? feedback@clareohealth.com

Product

How it works
Pricing
For Providers
Trials

Company

About
Blog
FAQ

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Positron Emission Tomography (PET) Imaging of Chemotherapy-Induced Cardiotoxicity

NCT07838649·1 site·ClinicalTrials.gov

What this study is about

Take this into the appointment.

Saves the questions and what to expect into your notes, next to the visit they belong to.

Keep this study

Molly Mohrman
CONTACT
314-747-4633 mohrmanm@wustl.edu
Pamela Woodard, MD
CONTACT
314-362-7100 woodardp@wustl.edu

Lead

Washington University School of Medicine

With

National Heart, Lung, and Blood Institute (NHLBI)

Age

21–99

Sex

ALL

Healthy volunteers

Not accepted

You may be eligible if

Men and women, 21-99 years of age and any race
Normal left ventricular function (left ventricular ejection fraction (LVEF) \>50%) as determined by echocardiography
HER2 positive or negative breast cancer patients or lymphoma patients
Designated to receive standard of care (SOC) treatment with an anthracycline-containing regimen including combination therapy
Patients willing to adhere to fasting for 15 hours before 18F-FDG PET imaging studies (if applicable)

You may not be if

Inability to receive and sign informed consent
Prior exposure to anthracyclines or other cardiotoxic drug
Contraindications to anthracycline chemotherapy
Patients with history of myocardial infarction
Patients with fasting blood sugar \>200 mg/dL or \<70 mg/dL and symptomatic
Contraindications to MR imaging (ferromagnetic implants, pacemaker, brain aneurysm clips, shrapnel, claustrophobia, etc.)
Pregnant or lactating. All female subjects of childbearing potential must have a documented negative pregnancy test (serum or urine hCG) performed within 24 hours immediately prior to the administration of 68Ga-Galmydar or documented post-menopausal defined as the cessation of menses for ≥ 12 months or documentation of having a bilateral oophorectomy and/or hysterectomy.
Any condition that in the opinion of the Principal Investigator or designee could increase risk to the participant, limit the participant's ability to tolerate the research procedures or interfere with collection of the data such as:
* Inability to lie still or unable to tolerate a supine position with arms up over the head or down at sides for up to a 60-minute PET scan due to chronic back/shoulder pain or arthritis as assessed by physical examination and/or medical history

The record

StatusNot yet recruiting

PhasePhase 1

Taking part36

StartedNov 2026

UpdatedSep 24, 2026

Conditions

Lymphoma Cancer Breast Cancer Cancer of the Breast Non-Hodgkin Lymphoma Hodgkin Lymphoma

Where1

Washington University School of Medicine
St Louis, Missouri, United States